Valiant Labs: Rights Issue Funds Utilized as Per Plan for Q3FY26
Valiant Laboratories Limited's Monitoring Agency Report for Q3FY26 confirms no deviation in the utilization of funds from its Rights Issue. Proceeds of ₹8,146.88 Lakhs were used for promoter loan adjustments, capex, and general corporate purposes. A total of ₹8,055.34 Lakhs has been utilized, with ₹91.54 Lakhs remaining.
The announcement provides clarity on the utilization of funds from a significant fundraising event (Rights Issue), which is important for investor confidence. However, it does not introduce new material business developments or immediate financial performance changes.
The report confirms that the company has utilized the funds raised through the Rights Issue as per the stated objects in the offer document, indicating good corporate governance and adherence to financial plans.
Valiant Laboratories Limited has submitted its Monitoring Agency Report for the quarter ended December 31, 2025, confirming the appropriate utilization of funds raised through its Rights Issue. The report, issued by India Ratings and Research Private Limited, was reviewed by the Audit Committee and the Board of Directors on February 11, 2026.
The Rights Issue, which took place from July 28, 2025, to August 08, 2025, involved the issuance of 1,08,62,500 equity shares at ₹75 per share, aggregating to ₹8,146.88 Lakhs. The funds were earmarked for adjusting unsecured loans of promoters, repayment of loans to promoter Dhanvallabh Ventures LLP, capital expenditure, and general corporate purposes.
The report confirms no deviation from the stated objects of the issue. A total of ₹8,055.34 Lakhs has been utilized as of December 31, 2025, with ₹91.54 Lakhs remaining unutilized. The unutilized amount primarily pertains to capital expenditure and general corporate purposes. The company has also reported that ₹44.37 Lakhs were utilized for issue-related expenses, with the balance of ₹25.63 Lakhs adjusted towards general corporate purposes, as actual expenses were lower than initially estimated. The report also details a fixed deposit of ₹91.75 Lakhs with HSBC Bank, maturing on February 12, 2026, as the deployment of unutilized proceeds.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.